• 1
    Khwaja K, Asolati M, Harmon JV et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 2004; 78: 13971399.
  • 2
    Woodle ES, Vincenti F, Lorber MI et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 2005; 5: 157166.
  • 3
    Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306311.
  • 4
    Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845850.
  • 5
    Ter Meulen CG, Van Riemsdijk I, Hene RJ et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004; 4: 803810.
  • 6
    Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 10891090.
  • 7
    Matas AJ, Kandaswamy R, Humar A et al. Long-term immunosuppression without maintenance prednisone after kidney transplantation. Ann Surg 2004; 240: 510516.
  • 8
    Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the Campath-1 (CDw52) antigen. Mol Immunol 1993; 30: 10891096.
  • 9
    Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative Campath 1H and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998; 351: 17011702.
  • 10
    Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 15: 120129.
  • 11
    Knechtle SJ, Pirsch JD, Fechner JH Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722730.
  • 12
    Knechtle SJ, Fernandez LA, Pirsch JD et al. Alemtuzumab-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136: 754760.
  • 13
    Ciancio G, Burke GW, Gaynor JJ et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 15: 426433.
  • 14
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 163168.
  • 15
    Axelrod D, Leventhal JR, Gallon LG, Parker MA, Kaufman DB. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas kidney transplant recipients. Am J Transplant 2005; 5: 14231429.
  • 16
    Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 13961399.
  • 17
    Kiberd BA, Lawen J, Fraser AD, Keouogh-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 10791083.
  • 18
    Budde K, Fritsche L. Proposal for guidelines for publication of randomized trials in the American Journal of Transplantation. Am J Transplant 2005; 5: 644647.